Prognosis
Brand-Name Drugmakers Turn on Each Other in Fight for New Market
- Company tells FDA J&J, Roche, Amgen engage in scare tactics
- Pfizer biosimilar sales have totaled less than $1 billion
This article is for subscribers only.
Pfizer Inc.’s multibillion-dollar gamble on cheaper versions of costly biotechnology drugs has turned into an all-out war of words with its pharmaceutical rivals.
In court, regulatory filings and online, New York-based Pfizer has gone up against Johnson & Johnson, Amgen Inc. and Roche Holding AG, making the case that its competitors are blocking access to Pfizer’s products and misleading patients to protect their lucrative franchises.